Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

cangrelor vs. clopidogrelCangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that have not previously received any other P2Y12 inhibitor.

 

The CHAMPION PHOENIX trial randomized a total of 11,145 patients to cangrelor vs. clopidogrel.

 

The study sought to explore the effect of cangrelor on peri-procedural acute myocardial infarction (AMI) according to different definitions.

 

462 patients (4.2%) undergoing PCI presented acute MI according to the 2nd universal definition. The vast majority of these infarctions were type 4A (n=433, 93.7%).

 

Treatment with cangrelor reduced MI incidence at 48 hrs. (3.8% vs. 4.7%; OR 0.80; CI 95%, 0.67-0.97; p=0.02).

 

When the SCAI definition of peri-procedural MI was applied, there were fewer MI (n=134). In addition, the effect of cangrelor remained significant (OR, 0.65; CI 95%, 0.46-0.92; p=0.01).

 

A similar effect of cangrelor was observed when MI was defined as peak CK-MB≥ 10x ULN (OR, 0.64; CI 95%I, 0.45-0.91) or when MI was defined with this same enzyme elevation but associated to ECG changes or ischemic symptoms (OR, 0.63; CI 95%, 0.48-0.84).

 

Any of the above definitions of MI were associated with an increased risk of death at 30 days.

 

Cangrelor administration reduced:

  • The composite death point of death.
  • MI (SCAI definition).
  • Ischemia driven target lesion revascularization or definite stent thrombosis (1.4% vs 2.1%; OR 0.69; 95% 0.51-0.92).

 

Conclusion

Peri-procedural MI in patients undergoing PCI continues to be associated to increased death risk, regardless MI definition. Cangrelor, compared to clopidogrel, significantly reduces MI rate.

 

Original Title: Consistent Reduction in Peri-Procedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX. Cangrelor Reduces MI in Patients Undergoing PCI.

Reference: Cavender et al. 10.1161/CIRCULATIONAHA.115.020829.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...